MEtatastic Renal Carcinoma LINes

• Conditions: Renal Cell Carcinoma

• Registration Number: NCT03928964
• Lead Sponsor: Centre Hospitalier Universitaire de Besancon

Brief Summary

The hypothesis of this study are as follows:

* Prognostic evaluation of patients based on an integrative model provides better assessment of overall survival, and thus improves setting of care goals.

* In a routine care population, antitumour drugs may have a significant impact on overall survival through their targeted antitumor effect, but also through their toxicity profile and their impact on comorbidities.

* The optimization of patient support (supportive care, drug tolerance monitoring) can have an impact on the prognosis.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-15
• Primary Completion: 2018-10-03
• Status Verified: 2019-04
• Study Completion: 2019-04
• Study First Submitted: 2019-04-24
• Study First Submitted QC: 2019-04-24
• Study First Posted: 2019-04-26
• Last Update Submitted: 2019-04-26
• Last Update Posted: 2019-04-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 440

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival after the first line of treatment	year 11	Time elapsed between initiation date for 2nd line treatment et the date of death, whatever the cause.

Trial Locations

Locations (8)

CHU de Besançon; 🇫🇷 Besançon, France

Hôpital Henri Mondor; 🇫🇷 Créteil, France

Hôpital Nord Franche-Comté Montbéliard; 🇫🇷 Montbéliard, France

Hôpital Cochin; 🇫🇷 Paris, France

Hôpital Européen Georges Pompidou; 🇫🇷 Paris, France

Hôpital Saint-Louis; 🇫🇷 Paris, France

Institut Mutualiste Montsouris; 🇫🇷 Paris, France

Hôpital d'Instruction des Armées de Bégin; 🇫🇷 Saint-Mandé, France